1,912,620 Shares in Recursion Pharmaceuticals, Inc. $RXRX Purchased by Nuveen LLC

Key Points

• Nuveen LLC has acquired 1,912,620 shares of Recursion Pharmaceuticals, valued at approximately $10.1 million, representing about 0.48% of the company.
• Analysts have given Recursion Pharmaceuticals a consensus rating of "Hold" with an average target price of $7.00, indicating mixed outlooks on the company's stock.
• Recursion Pharmaceuticals reported a 33.3% year-over-year revenue increase for the latest quarter, yet its earnings per share were below analysts' expectations.

Nuveen LLC bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,912,620 shares of the company's stock, valued at approximately $10,118,000. Nuveen LLC owned approximately 0.48% of Recursion Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC raised its holdings in Recursion Pharmaceuticals by 39.0% during the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after acquiring an additional 2,026 shares in the last quarter. NewEdge Advisors LLC raised its holdings in Recursion Pharmaceuticals by 43.7% during the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock worth $53,000 after acquiring an additional 2,387 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Recursion Pharmaceuticals during the fourth quarter worth about $54,000. San Luis Wealth Advisors LLC bought a new stake in Recursion Pharmaceuticals during the first quarter worth about $54,000. Finally, ADG Wealth Management Group LLC bought a new stake in Recursion Pharmaceuticals during the first quarter worth about $55,000. Institutional investors own 89.06% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Needham & Company LLC restated a "buy" rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, July 8th. Morgan Stanley assumed coverage on Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price objective on the stock. Two analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $7.00.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ RXRX opened at $4.94 on Friday. The firm has a market cap of $2.14 billion, a P/E ratio of -2.78 and a beta of 0.93. The company has a current ratio of 3.58, a quick ratio of 3.58 and a debt-to-equity ratio of 0.02. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36. The business's 50 day moving average is $5.46 and its 200-day moving average is $5.76.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). The firm had revenue of $19.10 million for the quarter, compared to the consensus estimate of $15.38 million. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.Recursion Pharmaceuticals's revenue for the quarter was up 33.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.40) EPS. Equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, insider Najat Khan sold 36,599 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $5.52, for a total transaction of $202,026.48. Following the transaction, the insider owned 668,197 shares in the company, valued at approximately $3,688,447.44. This trade represents a 5.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.43% of the company's stock.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Want to see what other hedge funds are holding RXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.